Dr John James will be speaking on Exploring the mechanism of T-cell receptor-mediated decision making: how does a receptor count to ten? as part of the Institute's seminar series, on 24 April. More...
Dr Klaus Okkenhaug has a long-standing interest in the roles of phosphoinositide 3-kinase (PI3K) enzyme isoforms in immune activation, particularly in T and B cells. His research group is based at the Laboratory of Lymphocyte Signalling and Development at the Babraham Institute and he currently holds a Wellcome Trust New Investigator Award. More...
The Institute of Immunity, Infection and Transplantation will serve as a translational research hub to develop new treatments and improve the management of patients with an immune-related disease.
- For patients, it will offer greater access to cutting-edge research and the latest treatments.
- For researchers, it will offer a critical mass of expertise for collaboration and synergy, and access to a broad and diverse patient population.
- Educational programmes will train doctors and scientists, creating a new elite generation of immunity and infection experts.
Key expertise includes:
- Discovering and developing new forms of therapy by performing first-in-man proof of principle studies
- Proof of concept studies which can serve as pathway finders to accelerate innovation in other disease areas
- Accelerated delivery of commercially sponsored phase II/III efficacy studies
- Working with industry to produce new vaccines and therapeutic cells as commercial products
We aim to establish a culture and infrastructure that attracts the best clinicians and scientists who provide innovative treatment options for our patients. Public awareness campaigns will raise the knowledge of immune system defects with the aim of improving prevention and early diagnosis of disease.
Page last modified on 29 jul 13 15:32